Industry Daily Summary
Industry Daily Summary: What Happened on November 2, 2026
Alligator sells mitazalimab rights to Biossil for $750,000 upfront
Fresenius and WuXi formed a biosimilar alliance.
-
P
Today in brief
Biossil will take over worldwide rights to Alligator Bioscience’s mitazalimab, paying $750,000 upfront plus potential milestones and royalties.1 The transfer shifts future development costs to Biossil after Alligator halted independent development in July.1
Also worth knowing
-
P
Fresenius and WuXi formed an alliance focused on biosimilars.2
Also published
- What is it Like to Go From Treating Patients Directly to Running a Company? Pharmaceutical Executive
- Breaking the silos: What effective scenario modeling looks like in 2026 and beyond BioPharma Dive
- Evolution Summit 2027 to Convene Senior Clinical Development Leaders in Westlake Village, California pharmaphorum
- Notable TechBio startups and companies operating in Thailand 🇹🇭 MetaphysicalCells